Macrogenics Stock Investor Sentiment

MGNX Stock  USD 2.22  0.02  0.91%   
Slightly above 51% of MacroGenics' investor base is interested to short. The analysis of the overall investor sentiment regarding MacroGenics suggests that many traders are impartial. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
  

MacroGenics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards MacroGenics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at www.macroaxis.com         
Acquisition by Jackson Scott Thomas of 4500 shares of MacroGenics subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
Apyx Medical Reports Q4 Loss, Tops Revenue Estimates
Yahoo News
few days ago at news.google.com         
MGNX LAWSUIT ALERT Levi Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and...
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Beth Smith of 1583 shares of MacroGenics subject to Rule 16b-3
Macroaxis News
over a week ago at gurufocus.com         
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Macrogenics Stock Hits 52-Week Low at 2.31 Amid Sharp Decline By Investing.com - Investing.com South...
Google News at Macroaxis
over two weeks ago at news.google.com         
MACROGENICS Earnings Preview Recent MGNX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Google News at Macroaxis
over two weeks ago at simplywall.st         
MacroGenics, Inc. Not Doing Enough For Some Investors As Its Shares Slump 26
Simply Wall St News at Macroaxis
over two weeks ago at kalkinemedia.com         
Could This Biopharmaceutical Developer Advance Cancer Treatment?
news
over two weeks ago at news.google.com         
MacroGenics Extends CEOs Separation Agreement - TipRanks
Google News at Macroaxis
over three weeks ago at news.google.com         
Disposition of 13332 shares by Jeffrey Peters of MacroGenics subject to Rule 16b-3
Google News at Macroaxis
over three weeks ago at finance.yahoo.com         
The past year for MacroGenics investors has not been profitable
Yahoo News
over three weeks ago at gurufocus.com         
Disposition of 16665 shares by Eck Stephen L. of MacroGenics subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a month ago at gurufocus.com         
WASATCH ADVISORS LP Acquires Additional Shares in Macrogenics Inc
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
Further weakness as MacroGenics drops 11 percent this week, taking one-year losses to 86
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about MacroGenics that are available to investors today. That information is available publicly through MacroGenics media outlets and privately through word of mouth or via MacroGenics internal channels. However, regardless of the origin, that massive amount of MacroGenics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MacroGenics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MacroGenics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MacroGenics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MacroGenics alpha.

MacroGenics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
01/02/2025
2
Acquisition by Ferrante Karen Jean of 4500 shares of MacroGenics subject to Rule 16b-3
01/08/2025
3
Macrogenics Stock Hits 52-Week Low at 2.95 Amid Market Challenges - MSN
01/17/2025
4
Investigation Alert MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Info...
02/06/2025
5
Disposition of 3475 shares by Jeffrey Peters of MacroGenics at 2.6 subject to Rule 16b-3
02/07/2025
6
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 RD Milestones
02/10/2025
7
MacroGenics Extends CEOs Separation Agreement - TipRanks
02/26/2025
8
Acquisition by Beth Smith of 1583 shares of MacroGenics subject to Rule 16b-3
03/07/2025
9
Acquisition by Jackson Scott Thomas of 4500 shares of MacroGenics subject to Rule 16b-3
03/14/2025

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.